Hua Hai Pharmaceutical Industry: The company and its subsidiaries obtained drug registration certificates.

Hua Hai Pharmaceutical announced that the company and its wholly-owned subsidiary, Pharmaceutical Technology, recently received drug registration certificates for the metoprolol succinate tablets, perindopril amlodipine tablets, and ramipril tablets issued by the National Medical Products Administration. Metoprolol succinate tablets are used to treat non-valvular atrial fibrillation in adult patients, prevent stroke and systemic embolism, with a predicted sales amount of approximately 615 million yuan in 2025. Perindopril amlodipine tablets are used as monotherapy for adult patients with uncontrolled hypertension, with a predicted sales amount of approximately 612 million yuan in 2025. Ramipril tablets are used for primary hypertension, with a predicted sales amount of approximately 131 million yuan in 2025.